BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (Nasdaq: ARRY) today announced that clinical data will be presented on its p38 inhibitor, ARRY-797 and its MEK inhibitor, ARRY-162, at the 2008 ACR/ARHP Annual Scientific Meeting in San Francisco, Calif.
